**Core tip:** In the modern era of adaptive radiotherapy, it is crucial to understand how different imaging techniques interact and complement each other for application in cancer care. The quantitative imaging metrics, apparent diffusion coefficient and standardized uptake value, play a significant role in understanding the efficacy of the radiotherapy treatment. Tumor cellularity and glucose metabolism were investigated before, during, and after radiotherapy in human papillomavirus negative head and neck squamous cell carcinoma patients using the diffusion-weighted magnetic resonance imaging and ^18^F-labeled fluorodeoxyglucose positron emission tomography/computed tomography imaging techniques.

INTRODUCTION
============

The Spanish Cancer Registries reported that in 2014, 241284 new cases of cancer were diagnosed in Spain\[[@B1]\]. Out of these, 12696 were head and neck (HN) cancers in which approximately 90% were specifically squamous cell carcinomas (SCC)\[[@B2]\]. The main subgroup for the patients was oropharyngeal SCC wherein 52%-72% of the cases were caused by infection from the human papillomavirus (HPV)\[[@B3]\]. It has been previously reported that HPV negative (-) HNSCC patients have poor outcomes compared with HPV-positive (HPV+) cancers\[[@B4]\]. Thus, in an effort to perform biologically guided adaptive radiotherapy, it is critical to understand how different functional imaging techniques interact and potentially complement each other\[[@B5]\]. Multimodality imaging, such as diffusion-weighted magnetic resonance imaging (DW-MRI) and ^18^F-labeled fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG-PET/CT), can provide useful anatomical and functional quantitative imaging metrics.

DW-MRI provides a noninvasive measurement for the degree of random motion of water in tissue; the rate of this diffusion is quantified by a quantitative imaging metric, the apparent diffusion coefficient (ADC)\[[@B6]\]. The advantage of DW-MRI over traditional anatomical MRI is that it can reflect the tissue cellularity and the integrity of cell membranes\[[@B7]\]. A recent metaanalysis reported that ADC has an inverse correlation with tissue cell density\[[@B8]\]. Kim et al\[[@B9]\] have shown that a significant increase in ADC was observed within 1 wk of treatment in HNSCC patients who were complete responders (*P* \< 0.01). The Vandecaveye et al\[[@B10]\] study further established the utility of ADC in differentiating responding from non-responding HNSCC by providing a threshold (25% and 20% for primary tumors and lymph node metastases, respectively) for the percent relative (Δ) ADC change between pre-treatment (Tx) and 3 wk post-chemoradiotherapy (post-CRT).

Another quantitative imaging metric, standardized uptake value (SUV), obtained from ^18^F-FDG PET is a measure of glucose metabolism. An abnormally elevated SUV can be observed in most primary and metastatic cancers including HNSCC\[[@B11]\]. The ^18^F-FDG PET/CT has an established role in HNSCC management, including staging and monitoring CRT response\[[@B12],[@B13]\]. The Schwartz et al\[[@B14]\] study showed that primary tumor SUV was a promising prognostic factor in HNSCC patients.

A better understanding of the association between ^18^F-FDG PET/CT and DW-MRI derived quantitative imaging metrics is needed in order for them to become the building blocks for a biologically-guided adaptive radiotherapy. Recently there have been few reports showing correlations between these multimodality imaging techniques and their initial role in the prognosis of HNSCC patients\[[@B15]\]. However, there are limited studies initiated to explore the use of these techniques together in a treatment planning setting for radiation oncology\[[@B16]\]. Our study is the first experience in Spain with multimodality imaging in HPV- HNSCC patients for its use in biologically-guided adaptive radiotherapy. The purpose of the current study is to noninvasively investigate tumor cellularity measured using DW-MRI and glucose metabolism measured by ^18^F-FDG-PET/CT during RT for HPV- HNSCC.

MATERIALS AND METHODS
=====================

Patients
--------

This prospective study was conducted in accordance with the Declaration of Helsinki\[[@B17]\]. The study protocol was approved by the local ethics committee; informed consent was obtained from all patients. All patients eligible for this study had biopsy-proven newly diagnosed squamous cell carcinoma of the head and neck. Diagnostic biopsies were also performed to evaluate HPV status. Six HPV- HNSCC patients underwent a total of 34 multimodality imaging examinations \[DW-MRI at 1.5 T Philips MRI scanner (*n* = 24) pre-, during (2-3 wk) and post-Tx, and ^18^F-FDG PET/CT pre- and post-Tx (*n* = 10)\] (Figure [1](#F1){ref-type="fig"}). All the patients were treated with intensity-modulated radiation therapy (IMRT), and the prescribed doses varied between 66 Gy and 70 Gy to the local planning target volume (PTV). Patient characteristics are given in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of the patients involved in this study

  **Characteristics**              **Value**
  -------------------------------- -----------
  Demographics                     
  Mean age (yr)                    65
  Age range (yr)                   52-79
  Male/female                      5/1
  Location of primary tumor        
  Oropharynx                       6
  Metastatic loco-regional nodes   11
  Radiation therapy technique      IMRT
  Dose (Gy)                        66-70
  Fractions                        32
  Outcome                          
  Alive with disease               3
  Dead of disease                  2
  No evidence of disease           1

![Workflow representing the study design performed in all the patients. ^18^F-FDG: Fluorine-18 Fludeoxyglucose; PET/CT: Positron emission tomography/computed tomography; DW-MRI: Diffusion-weighted magnetic resonance imaging.](WJR-9-17-g001){#F1}

All the patients had a clinical follow-up as the standard of care and survival status was documented into groups at 1 year. The four groups for patients were as follows: No evidence of disease (NED), alive with disease (AWD), dead of disease (DOD), and dead of other causes (DOC). Additionally, local-regional and distant metastases statuses were noted for all patients\[[@B18]\].

DWI-MRI
-------

All MRI examinations were performed on a 1.5-Tesla Achieva scanner (Philips Healthcare, The Netherlands) with a Philips Sense Flex coil over the neck. For MRI, all patients were in the supine position with an immobilization system that was also used during the radiotherapy treatment delivery. A thermoplastic mask, head support, and flat table were used to minimize distortion and improve the registration process between the different imaging modalities. The head support and flat table were adapted to the MRI/safety requirements. The MRI protocol consisted of the standard anatomic MRI scans (T1-/T2-weighted images) and DW-MRI.

DW-MRI acquisition was performed using single-shot echo planar imaging (SS-EPI) with three b values (b = 0, 600 and 1000 s/mm^2^). Other parameters included repetition time (TR) = 5000 ms, echo time (TE) = 77-100 ms, number of excitations (NEX) = 2, field of view (FOV): 24 cm, and slice thickness = 6 mm. The total acquisition time for obtaining the DW-MRI data was approximately 5 min. The acquisition matrix of 120 × 97 was zero filled to 256 × 256 during image reconstruction.

^18^F-FDG PET/CT
----------------

A whole-body PET/CT scan was performed from head to thigh, 60 min after intravenous administration of approximately 370 MBq (± 10%) of ^18^F-FDG on a PET/CT Discovery scanner (GE Healthcare Bio-Sciences Corp.). The patient was placed in the supine position, with the same immobilization system as in the radiotherapy treatment delivery. Other parameters included a 70 cm axial FOV, a 218 × 218 matrix. Data was acquired in a 3-D mode. The pixel spacing was 5.47 mm with a slice thickness of 3.27 mm. The spatial resolution varied from 3.99 mm to 4.56 mm. PET images were corrected using the specific software of the equipment for attenuation, scatter, decay, dead time, random coincidences, and slice sensitivity.

Image analysis
--------------

All images were registered and analyzed using in-house software (Artfibio-tool)\[[@B19]\]. The registration for DW-MRI and ^18^F-FDG PET/CT datasets was a two-step process: (1) Manual registration: performing a manual alignment (translation and/or rotation) of the images (DWMRI, CT-Scan, PET-CT) interactively on-screen; and (2) Automatic Rigid Registration: Once the images were approximately aligned, a more precise alignment (full rigid transformation) was performed based on an iterative process evaluated by statistical metrics (Viola and Wells mutual information\[[@B20]\]). Using Artfibio-tool, the signal intensity values were extracted from the whole tumor volumes\[[@B19]\].

**DW-MRI:** According to Stejskal and Tanner's\[[@B21]\] and considering the monoexponential approximation (7), the ADC value was calculated using equation 1:

ADC = \[log~e~(s~0~/s~1~)\]/(b~1~-b~0~). (1)

Where S~1~ and S~0~ are signal values of the images at b values, b~1~ and b~0~, respectively, and ADC is the apparent diffusion coefficient.

Regions of Interest (ROIs) were delineated on the primary tumor and neck nodal metastases by an experienced neuroradiologist on the DW-MRI image (b  =  0 s/mm^2^). Before contouring the ROIs, the T1-T2-weighted images were used to determine localization and tumor extent.

Finally, a relative percentage (%) change in derived imaging metric (ADC) between pre- and i^th^ intra-Tx week (Wk) was calculated as follows:

ΔADC (%) = \[(ADC~i~-ADC~0~)/ADC~0~\] × 100. (2)

Where i^th^ represents intra-TX week for ADC metric value and ADC~0~ represents the pre-Tx metric value.

**^18^F-FDG PET/CT:** An experienced radiation oncologist matched the ROIs from the MR images with those of the PET/CT images and analyzed them qualitatively and quantitatively using the attenuation-corrected PET emission images. The ROIs were placed over the areas of focal ^18^F-FDG uptake in both the primary tumor and neck nodal metastases. The intensity of the ^18^F-FDG uptake in the ROIs was measured using the SUV normalized by the dilution volume\[[@B22]\]. The imaging data available in units of mCi per mL (mCi/mL) per voxel were decay-corrected to the time of injection and converted to SUV units.

Statistical analysis
--------------------

In the present study, data was analyzed from a total of 34 multimodality imaging studies \[DW-MRI (*n* = 24) pre-, during- (2-3 wk) and post-Tx and ^18^F-FDG PET/CT pre- and post-Tx (*n* = 10)\] to capture treatment response. Values were presented as mean ± SD. The mean value comparison was carried out using the Wilcoxon test. A Spearman correlation analysis was performed between SUV and ADC metric values, which we used to report the correlation and *P*-values. These correlations were reported using the standard guidelines\[[@B23]\] in which an absolute correlation of \< 0.3 was considered weak, 0.3-0.5 was considered moderate and 0.5-1.0 was considered strong. The significance level was set at *P* ≤ 0.05. All data analysis was performed using the R software/environment, an open source project that is distributed under the GNU General Public License\[[@B24]\].

RESULTS
=======

All 6 patients were untreated at the first time point of multimodality imaging, had biopsy-proven SCC, and were HPV-. Among the 6 patients, a total of 11 neck nodal metastases and 5 primary tumors were analyzed (3 patients had more than one node and 1 patient had an unknown primary tumor site). Patients were grouped as follows based on clinical outcome: NED = 1, AWD = 3, and DOD = 2 (Table [1](#T1){ref-type="table"}). A total of 34 multimodality imaging studies \[DW-MRI (*n* = 24) and ^18^F-FDG PET/CT (*n* = 10)\] were analyzed to capture RT response. The results showed a significantly strong negative correlation (ρ = -0.67, *P* = 0.01) between the pre-Tx mean SUV and the pre-Tx mean ADC for the 11 lymph nodes and 5 primary tumors (Figure [2](#F2){ref-type="fig"}).

![Relationship between pre-Tx mean standardized uptake value and pre-Tx mean apparent diffusion coefficient showing a significant strong negative inverse correlation. SUV: Standardized uptake value; ADC: Apparent diffusion coefficient.](WJR-9-17-g002){#F2}

A summary of the ADC mean for pre-Tx and during-Tx (2^nd^ and 3^rd^ weeks data were combined) from the three different survival groups as DOD, AWD and NED is shown in Table [2](#T2){ref-type="table"}. For a single patient who was NED at the last clinical follow-up, the MRI and the ^18^F-FDG PET/CT post-treatment showed no evidence of disease at the primary tumor site and neck nodal metastases. Figure [3](#F3){ref-type="fig"} shows the DW-MRI and ^18^F-FDG PET/CT images from a patient who was NED. The ADC values (mean ± SD) for the ROI drawn on the primary tumor were 0.85 ± 0.27 × 10^-3^ mm^2^/s, 1.49 ± 0.13 × 10^-3^ mm^2^/s for pre-Tx and Wk~2-3~ Tx, respectively. The ADC values for the ROIs in neck nodal metastases were as follows 0.86 ± 0.20 × 10^-3^ mm^2^/s, 1.39 ± 0.08 × 10^-3^ mm^2^/s for pre-Tx and Wk~2-3~ Tx (Table [2](#T2){ref-type="table"}). Pre-Tx SUV (mean ± SD) values for primary tumor and neck nodal metastases were 5.99 ± 0.61 and 6.06 ± 0.49, respectively.

###### 

Apparent diffusion coefficient metric values for human papillomavirus negative head and neck squamous cell carcinoma patients who were classified based on survival as dead of disease, alive with disease and no evidence of disease before, during and post- radiotherapy

  **MRI**              **DOD ADC mean (× 10^-3^ mm^2^/s)**   **AWD ADC mean (× 10^-3^ mm^2^/s)**   **NED ADC mean (× 10^-3^ mm^2^/s)**                               
  -------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------- ------------- -------------
  Pre-Tx               1.51 ± 0.36                           1.43 ± 0.58                           1.66 ± 0.41                           1.26 ± 0.19   0.85 ± 0.27   0.86 ± 0.20
  During Tx (2-3 wk)   1.92 ± 0.33                           1.54 ± 0.11                           2.12 ± 0.38                           1.41 ± 0.38   1.49 ± 0.13   1.39 ± 0.08
  Post-Tx              No primary                            0.98 ± 0.29                           No primary                            1.93 ± 0.22   No primary    No node

MRI: Magnetic resonance imaging; ADC: Apparent diffusion coefficient; AWD: Alive with disease; DOC: Dead of other causes; DOD: Dead of disease; NED: No evidence of disease.

![Representative no evidence of disease patient. A and G: Pre-Tx PET/CT of the primary tumor and a neck nodal metastasis; B and H: Primary tumor and representative neck nodal metastasis contoured over a T2-W MRI; C and I: Pre-Tx ADC map overlaid on T2-W MRI; D and J: Wk2-Tx ADC map overlaid on T2-W; E and K: Wk3-Tx ADC map overlaid on T2-W; F and L: T2-W MRI post-Tx with no evidence of primary tumor and neck nodal metastases. PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion coefficient; IMRT: Intensity modulated radiation therapy.](WJR-9-17-g003){#F3}

Three patients were AWD on the last clinical follow-up, and 1 patient had an unknown primary tumor site. Both, MRI and ^18^F-FDG PET/CT post-treatment showed no evidence of disease at the primary tumor site; however the neck nodal metastases were still present. Figure [4](#F4){ref-type="fig"} shows the DW-MRI and ^18^F-FDG PET/CT images from a patient who was AWD. The ADC values (mean ± SD) for the primary tumors were 1.66 ± 0.41 × 10^-3^ mm^2^/s, 2.12 ± 0.38 × 10^-3^ mm^2^/s for pre-Tx and Wk~2-3~ Tx, respectively. The ADC values for the neck nodal metastases were 1.26 ± 0.19 × 10^-3^ mm^2^/s, 1.41 ± 0.38 × 10^-3^ mm^2^/s, and 1.93 ± 0.22 × 10^-3^ mm^2^/s for pre-Tx, Wk~2-3~ Tx and post-Tx, respectively (Table [2](#T2){ref-type="table"}). The SUV mean pre-Tx values for the primary tumor and neck nodal metastases were 1.84 ± 0.83 and 4.85 ± 0.75, respectively.

![Representative alive with disease patient. A and G: pre-Tx PET/CT of the primary tumor and two neck nodal metastases; B and H: Primary tumor and representative neck nodal metastasis contoured over a T2-W MRI; C and I: Pre-Tx ADC map overlaid on T2-W MRI; D and J: Wk2-Tx ADC map overlaid on T2-W; E and K: Wk3-Tx ADC map overlaid on T2-W; F and L: T2-W MRI post-Tx with no evidence of primary tumor but with presence of neck nodal metastasis. PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion coefficient; IMRT: Intensity modulated radiation therapy.](WJR-9-17-g004){#F4}

The two patients who were DOD died 2 mo and 6 mo post-Tx. Figure [5](#F5){ref-type="fig"} shows the DW-MRI and ^18^F-FDG PET/CT images from a patient who was DOD. The ADC values (mean ± SD) for the primary tumor were 1.51 ± 0.36 × 10^-3^ mm^2^/s and 1.92 ± 0.33 × 10^-3^ mm^2^/s for pre-Tx and Wk~2-3~ Tx, respectively. The ADC values for the neck nodal metastases were 1.43 ± 0.58 × 10^-3^ mm^2^/s, 1.54 ± 0.11 × 10^-3^ mm^2^/s, and 0.98 ± 0.29 × 10^-3^ mm^2^/s for pre-Tx, Wk~2-3~ Tx and post-Tx, respectively (Table [2](#T2){ref-type="table"}). The SUV mean pre-Tx values for the primary tumor and neck nodal metastases were 2.98 ± 0.66 and 3.93 ± 0.45, respectively.

![Representative dead of disease patient. A and G: Pre-Tx PET/CT of the primary tumor and three neck nodal metastases; B and H: Primary tumor and representative neck nodal metastasis contoured over a T2-W MRI; C and I: Pre-Tx ADC map overlaid on T2-W MRI; D and J: Wk2-Tx ADC map overlaid on T2-W; E and K: Wk3-Tx ADC map overlaid on T2-W; F and L: T2-W MRI post-Tx with no evidence of primary tumor but with presence of neck nodal metastasis. PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion coefficient; IMRT: Intensity modulated radiation therapy.](WJR-9-17-g005){#F5}

The ΔADC (%) between pre- and Wk~2-3~ Tx for primary tumors and neck nodal metastases were as follows: 75.4% and 61.6%, respectively, for the patient with NED, 27.5% and 32.7%, respectively, for those patients who were AWD, and 26.9% and 7.31%, respectively, for those who were DOD.

DISCUSSION
==========

This prospective study is the first in Spain conducted in support of integrating functional imaging in a RT setting. We evaluated multimodality imaging in HPV- HNSCC patients for both primary and neck nodal metastases. Specifically, we observed that pretreatment tumor cellularity is inversely proportional to glucose metabolism in these tumors, which was consistent with the previous literature\[[@B15],[@B25],[@B26]\]. The survival status and functional metrics show different % change in ΔADC for the NED, AWD, and DOD survival groups, which would need to be validated in larger patient population studies.

HNSCC is one of the major types of cancer that can be linked to alcohol consumption and tobacco smoking. It typically originates from the mucosal epithelia of the oral cavity, pharynx and larynx\[[@B27]\]. In oropharyngeal SCC, HPV status is an independent prognostic factor for both overall survival and progression-free survival, which is consistent with the hypothesis that HPV+ and HPV- tumors are distinct and have different causes, risk-factor profiles, and survival outcomes\[[@B28]\]. HPV- tumors continue to have poor outcomes compared to their HPV+ counterparts\[[@B28]\]. Future clinical trials should be designed specifically for patients with HPV+ or HPV- HNSCC using appropriate, validated quantitative imaging biomarkers. As there is very scarce imaging literature on HPV+ or HPV- alone, it raises an urgent need to study these cohorts independently and assess the value of multimodality imaging for better cancer patient management.

In recent years, studies by Razek have shown that ADC metric has a prognostic value in HNSCC\[[@B29]-[@B31]\]. They reported a mean ADC value in nasopharyngeal carcinoma (NPC) of 0.99 ± 0.11 × 10^-3^ mm^2^/s. The ADC value in this study also correlated inversely with tumor volume\[[@B29]\]. In a separate study by the same group, it was reported that the mean ADC value of residual or recurrent lesions (1.17 ± 0.33 × 10^-3^ mm^2^/s) was less than that observed in post-therapeutic changes (2.07 ± 0.25 × 10^-3^ mm^2^/s)\[[@B30]\]. They also showed that ADC values with metabolic ratio (Ch/Cr) obtained from 1H-MRS are well correlated with several prognostic parameters of HNSCC\[[@B31]\].

The use of multimodality imaging (^18^F-FDG PET/CT, DW-MRI, DCE-MRI) in general HNSCC populations for assessing both the association between the quantitative imaging biomarkers obtained from each imaging technique and their combined or respective roles in prognosis and/or prediction of outcome\[[@B8],[@B25],[@B32],[@B33]\]. The major technical challenges in IMRT persist in the use of functional images for treatment, one of which includes the identification of a reproducible, RT-compatible patient positioning setup that is consistent between functional techniques and RT. All patients in the present study were in a supine position and fixed in place with the same immobilization system that was used during the RT treatment planning and delivery. A thermoplastic mask, head support, and flat table were used to try to minimize distortion and to improve the registration process between the different imaging modalities. The head support and flat table were adapted to MRI and PET/CT. This reproducible positioning addressed one of the big hurdles in the acquisition of multimodality images that may be used for adaptive RT in the future\[[@B34],[@B35]\]. Dirix et al\[[@B36]\] designed a feasibility, prospective, multimodality imaging study with this prerequisite in mind, recruiting HNSCC patients for dose painting in RT. A pilot study by Subesinghe et al\[[@B37]\] emphasized the importance of reproducing the positioning for assessing early RT treatment response.

^18^F-FDG PET/CT and DW-MRI have been the focus of numerous studies in general HNSCC cohorts to determine correlation, if any, between SUV and ADC values, with variable results. SUV and ADC remain exploratory imaging metrics yet to be fully explored and understood in HPV-HNSCC patients. A study by Varoquax et al\[[@B38]\] involving 24 primary and 10 recurrent HNSCC showed no significant correlation between SUV values (SUV~max~, SUV~mean~ or SUV~min~) and ADC values (ADC~max~, ADC~mean~ or ADC~min~), nor did Choi et al\[[@B39]\] find significant correlation between SUV~mean~ and ADC~mean~ in 47 primary HNSCC. Rather, Nakajo et al\[[@B15]\] found significant negative correlation between SUV~max~ and ADC~mean~ in a study of 28 primary HNSCC tumors and Nakamatsu et al\[[@B26]\] demonstrated significant negative correlation in 41 neck nodal metastases between SUV values (SUV~max~, SUV~mean~) and ADC values (ADC~mean~, ADC~min~). In our study, similar results were obtained from a total of 11 neck nodal metastases and 5 primary HPV- HNSCC showing a significant strong negative correlation between the ADC~mean~ and SUV~mean~ pre-Tx (ρ = -0.67, *P* = 0.01). Further validation of the correlations with larger patient populations is needed, but was beyond the scope of this study. Preda et al\[[@B40]\] concluded in a study with 57 HNSCC primary tumors that "the combination of SUV~max~ and ADC~min~ improves the prognostic role of the two separate parameters".

The present study showed an increase in ΔADC Wk~2-3~ for the HPV- patient with NED in comparison with the DOD and AWD HPV- patients in both primary tumor and neck nodal metastases, in agreement with above-mentioned studies. Also, the pre-Tx ADC values of the primary tumor and neck nodal metastases for NED is lower than in the group of AWD and DOD, showing that lower pre-Tx ADC values are related to a good response to treatment and are consistent with the previous literature\[[@B9],[@B41]\].

The % change in ΔADC for primary tumor and neck nodal metastases depict the different Tx responses, suggesting the possibility of identifying HPV- patients with poor prognosis at an early stage to individualize and adapt RT treatment (*i.e*., through dose-escalation). Vandecaveye et al\[[@B42]\] showed in neck nodal metastases and primary tumors that ΔADC (Week 2 and Week 4 during CRT) was significantly lower (*P* \< 0.0001) in lesions with recurrence than in lesions with a complete response.

Individualization of treatment is especially important in the subgroup of HPV- patients who were part of this study. A limitation of the study was that there were a relatively small number of HPV- patients as the recruitment was highly selective in Spain. However, we felt that this selectivity was justified given that these subtypes of HPV- patients are the ones who have poor prognoses in HNSCC\[[@B28]\]. The initial results need to be addressed through validation in future studies.

Our study offers insight on how to manage and understand valuable quantitative imaging biomarkers, such as SUV and ADC for HPV- HNSCC, with the objective of integrating them into the development of biological adaptive RT in the future.

These results are preliminary in nature and are indicative, and not definitive, trends rendered by the imaging metrics due to the small sample size of HPV- HNSCC patients in a Meixoeiro Hospital of Vigo Experience.
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COMMENTS
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Background
----------

Human papillomavirus (HPV) negative (-) head and neck squamous cell carcinoma (HNSCC) patients have poor outcomes compared with HPV-positive (HPV+) cancers. Individualization of radiotherapy is especially important in the subgroup of HPV- patients and imaging metrics derived from multimodality imaging can be critical for its implementation.

Research frontiers
------------------

In an effort to perform biologically guided adaptive radiotherapy, it is critical to understand how different functional imaging techniques interact and potentially complement each other.

Innovations and breakthroughs
-----------------------------

Multimodality imaging in HPV- HNSCC suggests that tumor cell density is inversely proportional to glucose metabolism in a Meixoeiro Hospital of Vigo Experience. These results are promising and need to be validated in larger populations.

Applications
------------

Diffusion-weighted magnetic resonance imaging and ^18^F-labeled fluorodeoxyglucose positron emission tomography/computed tomography are two valuable imaging techniques that may help build the framework for adaptive radiotherapy based on functional images in future clinical trials by investigating tumor cellularity and glucose metabolism before, during and after RT in HPV- HNSCC.

Terminology
-----------

^18^F-FDG: Fluorine-18 fludeoxyglucose; ADC: Apparent diffusion coefficient; AWD: Alive with disease; DOC: Dead of other causes; DOD: Dead of disease; DW-MRI: Diffusion-weighted magnetic resonance imaging; HNC: Head and neck cancer; HNSCC: Head and neck squamous cell carcinoma; HPV-: Human papillomavirus negative; HPV+: Human papillomavirus positive; IMRT: Intensity modulated radiation therapy; MRI: Magnetic resonance imaging; NED: No evidence of disease; PET/CT: Positron emission tomography/computed tomography; ROI: Region of interest; RT: Radiotherapy.
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